Internationally, vaccines are one of the fastest growing sectors in the pharmaceutical and biotechnology industry. This project seeks to create a streamlined pathway for Australian vaccine development from the time of conception at the laboratory bench, typically in a University research lab, all the way through to human trials and commercialisation.
Whilst Australia has an exemplary record of basic immunology and vaccine research, there has been a major failure to capture the commercial value of this Australian research. This project will landscape the vaccine space, developing a free-to-use, publicly accessible database of all interested parties in the sector, and draw them together for the first Australian Vaccine conference in December 2017.
- A better connected Australian vaccine community, engaging through events and in person.
- Ten events have been held with over 350 attendees.
- Two products have been developed and 5 pre-clinical and one clinical trial have commenced.
Visit Vaxine to learn more.
Listen to Vaxine's Professor Nikolai Petrovsky on the quest for a COVID-19 vaccine
|Consortium lead||Vaxine Pty Ltd|
|Consortium members||Mylexa Pty Ltd, Australian Respiratory and Sleep Medicine Institute Ltd|
|Project duration||March 2017 - May 2018 (Completed)|
|Contact||Sharen Pringle, Vaxine - email@example.com|